Alteration of the Immune Response in Bacterial Infection (ARIIBACT)

The pilot study "ARIIBO" was conducted to analyze changes in immune parameters reported in obese subjects, which had never been the subject of a global study outside of an infectious context, and studied in period septic only sporadically. This study was intended to contribute to a better understanding of the probably adverse impact of obesity on the immune response to bacterial infections, and to describe a specific immunological profile of an infectious excess risk in obese subjects. In terms of infection, obesity is a risk factor due to "mechanical" and pharmacodynamic variations, but also to the immune system. One of the best studied immunological parameters in obese patients, leptin resistance, is associated with a decrease in innate and adaptive immunity through a modification of the lymphocyte and cytokine profile. It is important to compare the data collected in obese patients infected (first study called "ARIIBO"), with those of non-obese subjects presenting the same type of infection, which will be included in the study "ARIIBACT"

Description of an immunological profile of inflammation using current inflammatory cytokines during sepsis in non-obese subjects in comparison with this same profile in obese subjects

Description of the kinetics of 2 cytokines more speficically involved in obesity (leptine, adipokinine) during sepsis in non-obese subjects in comparison with this same profile in obese subjects

Description of the genetic polymorphism of leptine and leptine receptor in non-obese subjects in comparison with this same profile in obese subjects

Inclusion Criteria: age between 18 and 80 years BMI 18 to 25 presence of a bacterial infection pneumopathy (documented or probable) acute pyelonephritis / prostatitis skin and soft tissue infection (erysipelas, fasciitis, excluding pressure ulcers) cholecystitis / cholangitis, surgical site infection signed informed consent Exclusion Criteria: patients with documented viral, parasitic or mycotic infections patients with bacterial infection> 4 weeks (eg endocarditis, osteoarticular infections) patients followed in intensive unit care patients with progressive cancerous pathology or malignant hemopathy diagnosed in the previous five years patients with systemic diseases (connective tissue diseases, vasculitis) known immunodepression syndrome (CVID, HIV ...) immunosuppressive therapy in progress until less than one month before inclusion (corticosteroids, DMARDs, biotherapies, hydroxychloroquine)